Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Targeting a specific area for fat loss is the realm of surgery, not medication
Experts suggest that if the price differential is marginal, many patients may prefer the innovators brand due to its well-established efficacy, a trend previously observed with Novos insulin injectables
Therefore, when promoting tirzepatide, Eli Lilly, on the one hand, uses traditional methods, mainly through academic promotion and advertising to increase awareness, and at the same time focuses on strengthening insurance coverage to improve the accessibility of the drug
Phase 3 SURPASS trials began in 2019
10.1074/jbc.M105395200 J
US$ 29.63
US$ 24.15
US$ 29.33
US$ 26.02
